Syncom Formulations Reports Strong Q2 & H1 FY26 Financial Results with Significant Growth
Syncom Formulations reported robust Q2 and H1 FY26 results. Standalone and consolidated revenues and profits significantly increased year-over-year, driven by strong performance in the Pharmaceuticals segment.
The announcement indicates strong financial performance with significant year-over-year growth in revenue and profit, which is a key indicator of company health and can positively influence investor perception and stock valuation.
The company demonstrated substantial growth across all key financial metrics, including revenue from operations and profit for the period, on both a standalone and consolidated basis, for both the quarter and half-year ended September 30, 2025, compared to the previous year.
* Syncom Formulations (India) Limited announced its standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2025. * The Board of Directors approved these results at a meeting held on Wednesday, November 12, 2025, which concluded at 5:00 P.M. * Standalone Performance (Quarter Ended September 30, 2025): * Revenue from Operations: ₹12143.51 lakhs, up from ₹10149.25 lakhs in the same quarter last year. * Profit for the period: ₹1684.11 lakhs, significantly higher than ₹1095.00 lakhs in Q2 FY25. * Basic Earnings per Share (EPS): ₹0.18, compared to ₹0.16 in Q2 FY25. * Standalone Performance (Half Year Ended September 30, 2025): * Revenue from Operations: ₹23798.20 lakhs, an increase from ₹18735.68 lakhs in H1 FY25. * Profit for the period: ₹3257.04 lakhs, up from ₹1857.86 lakhs in H1 FY25. * Basic Earnings per Share (EPS): ₹0.39, compared to ₹0.27 in H1 FY25. * Consolidated Performance (Quarter Ended September 30, 2025): * Revenue from Operations: ₹12171.74 lakhs, up from ₹10231.42 lakhs in the same quarter last year. * Profit for the period: ₹1660.11 lakhs, significantly higher than ₹1110.82 lakhs in Q2 FY25. * Basic Earnings per Share (EPS): ₹0.18, compared to ₹0.16 in Q2 FY25. * Consolidated Performance (Half Year Ended September 30, 2025): * Revenue from Operations: ₹23861.91 lakhs, an increase from ₹18860.30 lakhs in H1 FY25. * Profit for the period: ₹3235.55 lakhs, up from ₹1873.83 lakhs in H1 FY25. * Basic Earnings per Share (EPS): ₹0.39, compared to ₹0.27 in H1 FY25. * The company operates in three segments: Pharmaceuticals Drugs & Formulations, Trading of Commodities, and Renting of Property. The Pharmaceuticals segment is the primary revenue driver. * The statutory auditors conducted a limited review for the quarter ended September 30, 2025, with no significant impact noted on the results.
What to do with a filing like this
Syncom Formulations (India) Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Syncom Formulations (India) Limited. Read the original for the full detail.